Pevonedistat

Drug Profile

Pevonedistat

Alternative Names: Captisol®-enabled pevonedistat; MLN-4924; TAK-924

Latest Information Update: 14 Jun 2017

Price : $50

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Takeda Oncology
  • Class 2 ring heterocyclic compounds; Amines; Antineoplastics; Cyclopentanes; Indenes; Pyrimidines; Pyrroles; Small molecules; Sulfonic acids
  • Mechanism of Action NEDD 8 activating enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • No development reported Haematological malignancies
  • Discontinued Solid tumours

Most Recent Events

  • 11 May 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Hungary (IV) (NCT03057366)
  • 10 May 2017 Discontinued - Phase-I for Solid tumours (Late-stage disease) in USA (IV) because of strategic portfolio decision (Takeda FY2016 results, May 2017)
  • 10 May 2017 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Hungary (IV) because of strategic portfolio decision (Takeda FY2016 results, May 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top